Objective To investigate the feasibility of low-dose CT perfusion imaging(CTPI)examination combined with iterative model reconstruction (IMR) in the brain.Methods 80 patients with clinical suspicion of acute cerebral infarction underwent the cerebral CTPI were enrolled in this study.30 normal hemispheres on group A [35 cases,80 kV,150 mAs, filtered back projection(FBP)] and group B(45 cases,80 kV,30 mAs, IMR) were selected to evaluate respectively.The pictures' subjective scores, effective radiation dose (ED),CT value,SD,signal to noise ratio(SNR), contrast to noise ratio(CNR) and the perfusion parameters of the grey matter (GM) and white matter(WM) in each hemisphere of the middle cerebral artery(MCA) territory were respectively compared at ASPECTS level 2 for the two groups.Results The ED were 2.52,0.50 mSv for group A,B.There were no statistical significances in the perfusion parameters,CT value, SD, CNR of the ROIs of the GM and WM,the SNR of the ROIs of the GM and the pictures' subjective scores between group A, B (P>0.05).There was statistical significance in the SNR of the ROIs of the WM between group A,B (P<0.05).Conclusion IMR combined with 30 mAs of the CTPI can reduce the radiation dose apparently while maintain the stability of the image quality and perfusion parameters.

Objective To investigate the prevalence of mutation in the locus 306 of embB gene in multi-drug resistant (MDR) Mycobacterium tuberculosis (TB) and evaluate the prospects for using it as a molecular marker to detect MDR-TB.Methods The 291 strains enrolled in this study were from the reference laboratory of Shanghai municipal centers for disease control and prevention, all of which had been tested for drug susceptibility.Mutation in embB 306 was screened both by amplification refractory mutation system (ARMS) and DNA sequencing.The mutation frequencies of embB 306 in the sample groups varied in drug resistance were statistically analyzed.Results 38(51.4% ) of the 74 MDR-TB were embB 306-mutant (X2 =93.8,P＜0.01).Of the 24 TB resistant to at least two drugs but not MDR, 9(37.5% ) were embB 306 mutant (X2 =60.1 ,P＜0.01 ).But only two(4.9% ) embB 306-mutant strains were found in 41 strains resistant to only one drug (X2 =6.8,P=0.0093).None embB 306-mutant strains were found in 152 pansensitive strains.The specificity of using embB 306 as a molecular marker for detecting multi-drug resistant TB was 94.9% (206/217).Conclusions As a molecular marker for screening drug resistant TB,especially MDR-TB, the gene locus embB 306 shows a relatively high sensitivity and specificity, promising a sound future for its application in clinics to realize fast screening of patients infected with MDR-TB and to provide evidence for appropriate medication.

Objective To analyze the changes of coagulation indexes in patients of non-valvular atrial fibrillation with different ABO blood types before and after treatment with the new oral anticoag-ulant dabigatran etexilate.Methods A total of 100 patients with non-valvular atrial fibrillation were selected as research subjects,and they were divided into type O group(n=50)and non-type 0 group(n=50)according to blood types,and dabigatran etexilate capsules were given to both groups.The coagulation function indexes of the two groups after 3 months were compared.Results Before treatment,there were significant differences in Von Willebrand factor(vWF)and protein C activities between two groups(P＜0.05).After treatment,the activities of vWF and protein C showed signifi-cant differences between two groups(P＜0.05).Before treatment,there was no significant differ-ence in activated partial thromboplastin time(APTT)between the two groups(P＞0.05),but there was a significant difference in APTT between the two groups after treatment(P＜0.05).There were no significant between-group differences in plasma prothrombin time(PT),thrombin time(TT),in-ternational normalized ratio(INR)and coagulation factor Ⅷ before and after treatment(P＞0.05).There were significant differences in all coagulation related indexes between the two groups after treat-ment compared with treatment before(P＜0.05).Conclusion Patients with type O blood are more likely to alert to occurrence of bleeding events when treated with dabigatran etexilate,and can be pre-dicted by APTT and protein C activity to some extent.

Objective To analyze the changes of coagulation indexes in patients of non-valvular atrial fibrillation with different ABO blood types before and after treatment with the new oral anticoag-ulant dabigatran etexilate.Methods A total of 100 patients with non-valvular atrial fibrillation were selected as research subjects,and they were divided into type O group(n=50)and non-type 0 group(n=50)according to blood types,and dabigatran etexilate capsules were given to both groups.The coagulation function indexes of the two groups after 3 months were compared.Results Before treatment,there were significant differences in Von Willebrand factor(vWF)and protein C activities between two groups(P＜0.05).After treatment,the activities of vWF and protein C showed signifi-cant differences between two groups(P＜0.05).Before treatment,there was no significant differ-ence in activated partial thromboplastin time(APTT)between the two groups(P＞0.05),but there was a significant difference in APTT between the two groups after treatment(P＜0.05).There were no significant between-group differences in plasma prothrombin time(PT),thrombin time(TT),in-ternational normalized ratio(INR)and coagulation factor Ⅷ before and after treatment(P＞0.05).There were significant differences in all coagulation related indexes between the two groups after treat-ment compared with treatment before(P＜0.05).Conclusion Patients with type O blood are more likely to alert to occurrence of bleeding events when treated with dabigatran etexilate,and can be pre-dicted by APTT and protein C activity to some extent.

Objective To investigate the effect of dapagliflozin on cardiac function and inflammatory factors of patients with type 2 diabetic mellitus(T2DM)with paroxysmal atrial fibrillation(PAF).Methods A total of 100 T2DM patients with PAF treated in Bengbu First People's Hospital from January 2021 to June 2022 were selected and divided into control group and observation group according to the treatment plan,with 50 cases in each group.Patients in both groups were given conventional treatment,and patients in observation group were given dapagliflozin on the basis of conventional treatment.Both groups were treated for 6 months.The cardiac function indexes and serum inflammatory factors were compared between two groups before and after treatment.Results After 6 months of treatment,left ventricular end diastolic diameter(LVEDD)and left atrium diameter(LAD)in both groups were significantly lower than before treatment,left ventricular ejection fraction(LVEF)was significantly higher than that before treatment,and serum hypersensitive C-reaction protein(hsCRP),interleukin-6(IL-6)and monocyte to high density lipoprotein-cholesterol ratio(MHR)were significantly lower than before treatment(P<0.05).LVEDD and LAD in observation group were significantly lower than those in control group,LVEF was significantly higher than those in control group,serum hsCRP,IL-6 and MHR were significantly lower than those in control group(P<0.05).Conclusion Dapagliflozin can significantly improve the cardiac function and reduce the level of inflammatory factors in T2DM patients with PAF,which has good clinical application value.

Objective To examine the anticancer effect of a novel histone deacetylase inhibitor (HDACi), JZ004, on colon cancer cells HCT-8 and HT-29, and to investigate the molecular mechanisms of proliferation inhibition and apoptosis induction of cancer cells treated by JZ 004.Methods Colon cancer cells were treated with a series of concentrations of JZ004 .MTT assay was used to detect the proliferation of cancer cells .The cell cycle distribution and apoptosis were deter-mined by flow cytometry .Rhodamine 123 and DCFH-DA were applied to detect the mitochondrial membrane potential (ΔΨm) and reactive oxygen species ( ROS) production.The protein expressions of acetyl-histone H3, p21, cyclin-dependent kinase(CDK)4, Bcl-2, Mcl-1 and Bax were assayed by Western blotting .Results JZ004 was found to inhibit proliferation and induce apoptosis of colon cancer cells in a time-and dose-dependent manner , accompanied by a dose-dependent hyperacetylation of histone H3.JZ004 induced the cancer cell arrest in G 0/G1 phase by increasing the expres-sion level of p21 while CDK4 was downregulated .JZ004 also increased cellular ROS production and reduced ΔΨm by regu-lating the expressions of Bcl-2 family proteins .Conclusion As a novel HDACi , JZ004 effectively inhibits proliferation and increases ROS production to induce apoptosis of colon cancer cells .The results indicate that JZ004 is a potential compound to be developed as an anti-colon cancer agent for clinic application .

Objectives To develop a multi-stage and multi-epitope vaccine, which consists of epitopes from the early secretory and latency-associated antigens of Mycobacterium tuberculosis (MTB). Methods The B-cell, cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes of 12 proteins were predicted using an immunoinformatics. The epitopes with antigenicity, without cytotoxicity and sensitization, were further screened to construct the multi-epitope vaccine. Furthermore, the proposed vaccine underwent physicochemical properties analysis and secondary structure prediction as well as 3D structure modeling, refinement and validation. Then the refined model was docked with TLR4. Finally, an immune simulation of the vaccine was carried out. Results The proposed vaccine, which consists of 12 B-cell, 11 CTL and 12 HTL epitopes, had a flexible and stable globular conformation as well as a thermostable and hydrophilic structure. A stable interaction of the vaccine with TLR4 was confirmed by molecular docking. The efficiency of the candidate vaccine to trigger effective cellular and humoral immune responses was assessed by immune simulation. Conclusion A multi-stage multi-epitope MTB vaccine construction strategy based on immunoinformatics is proposed, which is expected to prevent both active and latent MTB infection.
Mycobacterium tuberculosis/metabolism* ; Molecular Docking Simulation ; Toll-Like Receptor 4 ; Epitopes, T-Lymphocyte/chemistry* ; Epitopes, B-Lymphocyte/chemistry* ; Vaccines, Subunit/chemistry* ; Computational Biology/methods*